Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK)of its portfolio company EyeBio for a potential value of $3 billion This acquisition reflects the significant clinical progress
Foreign Affairs Provides up to the minute Raw News, reportage, current affairs, Open Source Intelligence, OSI, Information, Analysis, and Essays, all published with immediacy at the time of relevancy